Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of SAGE-217 in the Treatment of Adults With Severe Postpartum Depression

NCT04442503 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT04442503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04442503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of SAGE-217 in the Treatment of Adults With Severe Postpartum Depression
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
June 8, 2020
Completion date
April 12, 2022
Enrollment
200 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

depression, postpartum